| Quarter | Score |
|---|---|
| 2022-Q1 | 51.6 |
| 2022-Q3 | 66.8 |
| 2022-Q4 | 50.2 |
| 2023-Q1 | 50.4 |
| 2023-Q2 | 64.0 |
| 2023-Q3 | 48.0 |
| 2023-Q4 | 74.1 |
| 2024-Q1 | 71.6 |
| 2024-Q2 | 69.3 |
| 2024-Q3 | 75.4 |
| 2024-Q4 | 75.7 |
| 2025-Q1 | 76.4 |
| 2025-Q2 | 76.8 |
| 2025-Q3 | 75.7 |
| 2025-Q4 | 75.4 |
| 2026-Q1 | 75.4 |
| 2026-Q2 | 75.5 |
Funds reducing exposure or consensus momentum fading
Trading +64.4% above funds' purchase price — elevated pullback risk
2 of 18 tracked funds hold VRSN. Avg conviction: 0.4%. Net trimming. First tracked at $183.88 (current +64.4% vs tracked).
Berkshire Hathaway has 0.8% in this stock
Benchmark comparison unavailable
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Berkshire Hathaway | 0.8% | Hold |
| Citadel Advisors | 0.0% | Reduce |